Related Articles
Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer
Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature
The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab‑paclitaxel chemotherapy
FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) PLUS GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR (GM-CSF) IN ADVANCED OR INFLAMMATORY BREAST-CANCER - A DOSE-FINDING STUDY
Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy